Daily Traders Edge

: Biogen halts development of antibody drug aimed at Alzheimer’s

June 17
07:37 2021

Shares of Biogen Inc. fell nearly 1% in the extended session after the pharma company said it will halt the development of an antibody drug aimed at treating Alzheimer’s disease after a study showed no benefit to patients. Another of the company’s drugs aimed at the disease won approval earlier this month.

Continue Reading At MarketWatch

Related Articles

Newsletter Signup

Sign up for our free newsletter